Clinical trial · Observational
Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90
NCT04437420CI-TRIAL-00045641HSP-HEMATOunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
NVP-BEP800, a new HSP90 inhibitor, has particularly interesting therapeutic potential and represents hope in cancer pathologies. While it is currently being tested for solid cancers, no preclinical study has yet demonstrated its effectiveness in acute lymphoblastique leukemia (ALL). The investigators wish to study the effects of NVP-BEP800 on two different types of ALL (T and B-ALL).
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute B Lymphoblastic Leukemia (B-ALL) | B Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.80 |
| Acute T Lymphoblastic Leukemia (T-ALL) | T Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Control | Other | — | UNRESOLVED |
| injection of BEP 800 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- T-ALL
- interventionNames
- Drug: injection of BEP 800
- Other: Control
- label
- B-ALL
- interventionNames
- Drug: injection of BEP 800
- Other: Control
Primary outcomes (1)
- measure
- Viability on primary ALL samples
- timeFrame
- 2 years
- description
- The effect of BEP-800 after 48 hours of treatment on T-ALL and B-ALL will be evaluated by counting viable cells by flow cytometry with a viability marker and specific antibodies to detect leukemia cells.
Secondary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patient suffering from acute lymphoblastic leukaemia whose biological samples are kept at the Biology Technical Platform. Exclusion Criteria: * Patient over 80 years of age
References
Publications (0)
Data not yet available
No reference posted for this study.